Drug Trial Radar · NCT05886777
A Study to Learn About Two or More Vaccines That Are Put Together as One Shot Against Infectious Lung Illnesses, Including COVID-19 and Respiratory Syncytial Virus (RSV).
Last checked: Nov 19, 2026Latest source record: Dec 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,142
Actual
Start
Jun 5, 2023
Primary completion
Jan 1, 2024
Study completion Jan 1, 2024
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Jun 2, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to learn about the safety and effects of a combined vaccine for RSV and COVID-19 when given with a seasonal flu vaccine or when given alone. A combined vaccine will help to reduce the number of vaccinations given when trying to prevent respiratory infections. This study is seeking participants who: * are 65 years of age or older. * are healthy or have well-controlled chronic conditions. * in the past have received at least 3 US-authorized mRNA COVID 19 vaccines, with the most recent vaccine being an updated booster vaccine given at least more than or equal to 150 days before Visit A101 (Day 1). * have not had a flu shot in the last 120 days. * agree to be present for all study visits, procedures, and blood draws. Participants will be involved in this study for 6 months. During this time, participants will have 2 study visits at the study clinic and a 6-month telephone contact.
Conditions
- Healthy Participants
Interventions
Combination [RSVpreF+BNTb162b2]Biological
Combination of RSVpreF and Bivalent BNT162b2 given as a single intramuscular injection
Bivalent BNT162b2 (original/Omi BA.4/BA.5)Biological
Bivalent BNT162b2 given as an intramuscular injection
RSVpreFBiological
RSVpreF given as an intramuscular injection
QIVBiological
Licensed QIV given as an intramuscular injection
Normal Saline PlaceboBiological
Normal saline (0.9% sodium chloride solution for injection)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Local Reactions Within 7 Days After VaccinationTime frame: Day 1 to Day 7 after Vaccination on Day 1
- Percentage of Participants With Systemic Events Within 7 Days After VaccinationTime frame: Day 1 to Day 7 after Vaccination on Day 1
- Percentage of Participants With Adverse Events (AEs) Within 1 Month After VaccinationTime frame: Within 1 Month after Vaccination
- Percentage of Participants With Serious Adverse Events (SAEs) Within 6 Months After VaccinationTime frame: Within 6 Months after Vaccination
- Geometric Mean Titer (GMT) and Geometric Mean Ratio (GMR) of Neutralizing Titers (NTs) for Respiratory Syncytial Virus Subgroup A (RSV A) at 1 Month After Vaccination: Group 1 Versus Group 4Time frame: 1 Month after Vaccination
- GMT and GMR of NTs for Respiratory Syncytial Virus Subgroup B (RSV B) at 1 Month After Vaccination: Group 1 Versus Group 4Time frame: 1 Month after Vaccination
- GMT and GMR of NTs for SARS-CoV-2 Omicron BA.4/BA.5 at 1 Month After Vaccination: Group 1 Versus Group 3Time frame: 1 Month after Vaccination
- GMT and GMR of NTs for SARS-CoV-2 Reference Strain at 1 Month After Vaccination: Group 1 Versus Group 3Time frame: 1 Month after Vaccination
- GMT and GMR of the Strain-Specific Hemagglutination Inhibition (HAI) Titers (H1N1 A/Victoria) of QIV at 1 Month After Vaccination: Group 1 Versus Group 5Time frame: 1 Month after Vaccination
- GMT and GMR of the Strain-Specific HAI Titers (H3N2 A/Darwin) of QIV at 1 Month After Vaccination: Group 1 Versus Group 5Time frame: 1 Month after Vaccination
- GMT and GMR of the Strain-Specific HAI Titers (B/Austria) of QIV at 1 Month After Vaccination: Group 1 Versus Group 5Time frame: 1 Month after Vaccination
- GMT and GMR of the Strain-Specific HAI Titers (B/Phuket) of QIV at 1 Month After Vaccination: Group 1 Versus Group 5Time frame: 1 Month after Vaccination
- GMT and GMR of NTs for RSV A at 1 Month After Vaccination: Group 2 Versus Group 4Time frame: 1 Month after Vaccination
- GMT and GMR of NTs for RSV B at 1 Month After Vaccination: Group 2 Versus Group 4Time frame: 1 Month after Vaccination
- GMT and GMR of NTs for SARS-CoV-2 Omicron BA.4/BA.5 at 1 Month After Vaccination: Group 2 Versus Group 3Time frame: 1 Month after Vaccination
- GMT and GMR of NTs for SARS-CoV-2 Reference Strain at 1 Month After Vaccination: Group 2 Versus Group 3Time frame: 1 Month after Vaccination
Locations
37 sites in 1 country. Site status is shown where the registry gives one.
West Coast Research
Dublin, California
Marvel Clinical Research
Huntington Beach, California
Orange County Research Center
Lake Forest, California
Artemis Institute for Clinical Research
San Diego, California
California Research Foundation
San Diego, California
Orange County Research Center
Tustin, California
Diablo Clinical Research, Inc.
Walnut Creek, California
Clinical Research Consulting
Milford, Connecticut
Indago Research & Health Center, Inc
Hialeah, Florida
Wr-Msra.Llc
Lake City, Florida
Optimal Research
Melbourne, Florida
Suncoast Research Group
Miami, Florida
Clinical Site Partners, LLC dba CSP Orlando
Winter Park, Florida
Clinical Site Partners, LLC dba Flourish Research
Winter Park, Florida
Great Lakes Clinical Trials - Gurnee
Gurnee, Illinois
Optimal Research
Peoria, Illinois
Bio-Kinetic Clinical Applications LLC DBA QPS_MO (Patient Screening Only)
Springfield, Missouri
Bio-Kinetic Clinical Applications, LLC dba QPS-MO
Springfield, Missouri
Bio-Kinetic Clinical Applications, LLD dba QPS-MO
Springfield, Missouri
Las Vegas Clinical Trials
Las Vegas, Nevada
Las Vegas Clinical Trials
North Las Vegas, Nevada
Drug Trials America
Hartsdale, New York
Accellacare - Wilmington - 1917 Tradd Court
Wilmington, North Carolina
Accellacare - Wilmington
Wilmington, North Carolina
Centricity Research Columbus Ohio Multispecialty
Columbus, Ohio
Coastal Carolina Research Center
North Charleston, South Carolina
Clinical Research Associates Inc
Nashville, Tennessee
Headlands Horizons LLC
Brownsville, Texas
DM Clinical Research - Cy Fair
Houston, Texas
DM Clinical Research- Cyfair
Houston, Texas
DM Clinical Research - Bellaire
Houston, Texas
SMS Clinical Research
Mesquite, Texas
Clinical Trials of Texas, LLC
San Antonio, Texas
DM Clinical Research, Martin Diagnostic Clinic
Tomball, Texas
J. Lewis Research, Inc. / Foothill Family Clinic
Salt Lake City, Utah
J. Lewis Research, Inc. / Foothill Family Clinic South
Salt Lake City, Utah
Virginia Research Center
Midlothian, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.